Transkaryotic Therapies Replagal
Executive Summary
Company receives "complete review" letter for agalsidase alpha Jan. 1. FDA requests additional data and TKT "has initiated the collection of these data," the company says. Genzyme's Fabrazyme (agalsidase beta) is also receiving priority review at FDA for Fabry disease (1"The Pink Sheet" Dec. 18, 2000, p. 34)
You may also be interested in...
TKT, Genzyme Fabry Disease Products Nearing January Review Deadline
Transkaryotic Therapies and Genzyme are in a close race to introduce a Fabry disease enzyme replacement therapy.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials